Bernd R. Seizinger

Bernd Seizinger, M.D., Ph.D., has served asa member of our board of directors since 2016. Dr. Seizinger currently serves as chairman/board member in a number of public and private biotech companies in the U.S., Europe and Canada, including: Oxford BioTherapeutics, Aprea, CryptoMedix, Oncolytics and Biolnvent. Previously he was President & CEO of GPC Biotech; VP Oncology Drug Discovery and - in parallel - VP Corporate and Academic Alliances at Bristol-Myers Squibb; Executive VP and CSO, Genome Therapeutics; Senior Faculty positions at Harvard Medical School, Massachusetts General Hospital and Princeton University.